Drug intelligence / Profile preview

BiTE-EV

Development stage: Phase 1
Lead developer: Beijing Gaobo Hospital
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**BiTE-EV** is an investigational, mesenchymal-stem-cell-derived extracellular-vesicle immunotherapy for relapsed or refractory acute B-cell lymphoblastic leukemia. The product consists of extracellular vesicles displaying a bispecific T-cell engager directed against CD3 on T cells and CD19 on malignant B-lineage cells, with the intended effect of recruiting and activating cytotoxic T cells against CD19-positive leukemia cells. It is being evaluated by Beijing GoBroad Hospital in an early-phase clinical study, with no posted clinical results. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890494))

Other names: BiTE-EV

Targets

CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on BiTE-EV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiTE-EV.

Explore the full profile